Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, Nab-Paclitaxel, and Durvalumab in Locally Advanced or Metastatic Gallbladder Cancer
NCT06591650Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in gallbladder adenocarcinoma, sponsored by Fudan University. Primary endpoint: Objective Response Rate up to 36 months. Started Oct 2024; status: recruiting.
02
Drugs
durvalumab
03
Conditions
gallbladder adenocarcinoma
Beyond the preview
Go deeper on NCT06591650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06591650.